Dyne Therapeutics (DYN) has been in focus after back to back U.S. FDA milestones, including clearance to begin a Phase 1 trial for DYNE-302 and Priority Review for Duchenne candidate DYNE-251.

Recent regulatory milestones appear to be feeding into Dyne Therapeutics' share price momentum, with the stock at US$25.18 after a 15.56% 30 day share price return and a 150.55% 1 year total shareholder return, even as recent losses and the July follow on equity raise keep risk firmly in focus.

If you are looking beyond Dyne Therapeutics and want to see what else is moving in healthcare, this is a good moment to check out 41 healthcare AI stocks

After Dyne Therapeutics' sharp move following the FDA news and the July equity raise, the real tension now is between stepping in at US$25.18 or holding fire for a different entry. So what does the current valuation actually imply?

Dyne Therapeutics valuation: what the numbers are saying

On Simply Wall St's DCF model, Dyne Therapeutics has an estimated fair value of $40.88 compared with the current share price of $25.18, which points to a sizeable valuation gap. That fair value is 38.4% above where the stock last closed, so the model is indicating upside from current levels.

The SWS DCF model estimates the value of Dyne Therapeutics by projecting future cash flows and then discounting them back to today using a required return. This approach focuses on the cash the business is expected to generate rather than current earnings, which is relevant here because Dyne Therapeutics is a clinical stage company and currently reports losses of $519.41m with no meaningful revenue.

For a pre revenue biotech that is currently unprofitable and forecast to remain unprofitable over the next 3 years, a DCF framework helps anchor expectations to those forecast cash flows instead of near term earnings metrics. The model incorporates forecasts such as revenue growth that is expected to run at 65.3% per year, while also reflecting sector specific risks through the discount rate. The result is a fair value that investors can compare directly with the current $25.18 share price.

Result: DCF Fair value of $40.88 (UNDERVALUED)

However, Dyne Therapeutics is still pre revenue and reporting a loss of $519.41m, so any setback in its clinical programs could quickly hit sentiment.

Another view on Dyne Therapeutics valuation

While the SWS DCF model suggests Dyne Therapeutics is undervalued at $25.18 versus an estimated $40.88 fair value, the P/B picture looks less generous. DYN trades at 6.7x book value compared with 2.4x for the wider US Biotechs industry. That difference can mean more room for upside or just less margin for error. Which side do you think it leans toward?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Dyne Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Dyne Therapeutics showing both potential upsides and clear risks, this is a moment to look at the data yourself and decide quickly where you stand. To get a balanced view, start by reviewing the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Dyne Therapeutics?

If Dyne Therapeutics has sharpened your focus on opportunities, do not stop here. Broader ideas from the Simply Wall St screener can help round out your watchlist.

• Strengthen your core with companies that pair resilient finances and lower risk profiles through the 81 resilient stocks with low risk scores.
• Hunt for quality at a discount by scanning the 55 high quality undervalued stocks and see which stocks currently trade below their estimated worth.
• Spot potential future standouts early by reviewing the screener containing 19 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.